You Are Here    Publications   Patient specific information

Patient specific information

BHIVA guidelines summaries BHIVA guidelines summaries

BHIVA guidelines set out the medical and other care people living with HIV can expect to receive in the UK.

Non-technical versions of BHIVA guidelines are intended to support, rather than replace, consultation with a healthcare professional.

Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Click here to view non-technical versions of BHIVA guidelines.

Switching to Rezolsta (darunavir + cobicistat) or Evotaz (atazanavir + cobicistat)

Switching to Rezolsta (darunavir + cobicistat) or 
Evotaz (atazanavir + cobicistat) October 2016
Rezolsta (darunavir/cobicistat) and Evotaz (atazanavir/cobicistat) are new fixed dose combinations (FDC) combining the HIV protease inhibitors darunavir and atazanavir with the pharmacokinetic enhancer cobicistat. When switching from ritonavir-boosted darunavir or atazanavir to the respective FDCs there are multiple clinical differences that need to be considered for each patient. The Royal Free London and Chelsea & Westminster HIV teams have worked with the University of Liverpool HIV pharmacology team to produce a resource guide for clinicians making this switch. This has been endorsed by both BHIVA and FHIVA.

O
Download the leaflet

Updated post-exposure prophylaxis 
(PEP) leaflet Updated post-exposure prophylaxis (PEP) leaflet

October 2014
In response to the suggested changes to HIV Post-Exposure Prophylaxis (PEP) made by the expert advisory group on AIDS (EAGA), the patient information leaflet has been updated to reflect the new regimen.

The leaflet was written by the HIV Pharmacy Association (HIVPA) and endorsed by EAGA, BASHH and BHIVA.

The current PEPSE guidelines are undergoing review and new guidelines are expected in early 2015. This leaflet will be reviewed then providing an opportunity to amend any details. As part of the PEPSE guideline process, a patient information leaflet detailing the effectiveness and indications for PEPSE will be drafted for patients to read before agreeing to treatment.

Please use this as an advice leaflet for patients commencing PEP and add your contact details to it for further queries. Please note any editing/redrafting to the content requires removal of all endorsements from HIVPA, EAGA, BASHH and BHIVA.

O
Download the updated leaflet

HIV, GPs & other primary care HIV, GPs & other primary care

Effective treatment means that, for many people, HIV is now a long-term, manageable medical condition. Primary care services - those provided by general practitioners (GPs, or family doctors), dentists and other community-based medical services - can offer important services for people with HIV, providing long-term health care and support. This booklet explains the services they offer, how this care fits with HIV specialist care, and how to make the most of primary care services.  Click here for more information.


Download the NAM booklet produced in collaboration with BHIVA

Patient Information Leaflets (PILs) Patient Information Leaflets (PILs)

HIVPA produce a series of patient information leaflets (PILs) aimed at delivering the key information to patients. Many have been produced in collaboration with NAM.

As there is typically more than one supplier in the UK market for any generic they elected not to include any images or references to particular products. They are designed to be printed on A4 and either printed double sided, or single sided and cut down to A5.

Click here for more information